Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Ron Kertesz who wrote (1177)	2/10/1999 6:33:00 PM
From: Chuca Marsh	Respond to of 1501

Ron, you read me like a book...I was thinking on the when of jumping back in. The 60 days is a loooog time and and and and AND what you say! WOW! Thanks again Ron... If you are in Consulting still...I hope you have seen the Convertible Crapdentatures that the bios have done to this past years Market...MY Picks like Genzyme Transgenz, Cytogen...oh the list is endless! Now, IZP... I just got a blurb from Michael Murphy on how to enter the techs....he changed his name from California Technology Stock Letter ...to something else. It is the entry as well as the exit. I hold and drop, I got down pat! ChucKa

To: Ron Kertesz who wrote (1177)	2/10/1999 7:17:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 1501

Please don't take offense but when I read your message I read... blah... blah... blah...at Inflazyme's discretion...blah...blah...blah The stock is at $1.75 from $0.41. What is the concern?

To: Ron Kertesz who wrote (1177)	2/10/1999 8:10:00 PM
From: Harold Lehman	Read Replies (2) \| Respond to of 1501

Ron, There is never any guarantee on any product, medical or otherwise, for any company, listed on a stock exchange or otherwise. Your concerns about safety and efficacy are those seen for any company in the medical field with a new product under development. That said, I think that Inflazyme's chances, based on the preclinical studies, are about as good as you can see at that stage of development. I also spoke with Jeff Bacha, after you did, this afternoon. These financing terms are about as good as any you're ever going to see. Inflazyme doesn't have to request any of the $15 million US buyin unless they need it, and they don't have to request conversion into Inflazyme stock at that time. They can wait, after they're received the financing, until any time at which they see fit. So there is lots of time for stock price appreciation before conversion. As for the option agreement, this is pretty standard stuff. It simply means that they have entered into an agreement, subject to the scrutiny of each companies' legal personnel to make sure all the details are worded correctly and nothing is overlooked. The agreement was made at the highest levels of both companies. The percentage royalties to Inflazyme is in the double digit range, although Jeff could reveal the actual percentages to me since Hoechst doesn't want it made public at this time. Inflazyme may eventually have to reveal it if and when they file with the SEC or some other body (my conjecture for some other body), but until then they have to comply with their partner's wishes. Also, Hoechst showed a great deal of confidence in them by wanting Inflazyme to develop Hoechst's own compound for allergy treatment. Not to mention the same royalty structure holds for this one as well. Not a bad add-on IMO. One more thing. Inflazyme only has to develop these compounds through Phase IIa, then Hoechst completes the studies. If complete development is successful for both drug candidates then milestone payments can total up to $75 million US. Most of these are for the IPL 576 compound. I don't know what you consider to be a good deal, esp. for a small biotech company, but this looks pretty damn good to me. Sincerely, Harold